Skip to main content
. 2020 Nov 20;58(1):33–44. doi: 10.3892/ijo.2020.5150

Figure 2.

Figure 2

MAFG-AS1 sponges miR-150-5p. (A) Subcellular fractionation of the expression of MAFG-AS1 in the nucleus and cytoplasm of MCF-7 cells. #P<0.05 vs. cytoplasm. (B) Target binding between MAFG-AS1 and miR-150-5p. Red represents mutated bases. (C) The interaction between miR-150-5p and MAFG-AS1 was confirmed by luciferase reporter assay. #P<0.05 vs. NC mimics + WT-pGLO-MAFG-AS1. (D) The expression of MAFG-AS1 in MCF-7 and MDA-MB-468 cells transfected with miR-150-5p was determined by RT-qPCR. #P<0.05 vs. NC mimics. (E) The expression of miR-150-5p in MCF-7 and MDA-MB-468 cells transfected with pcDNA-MAFG-AS1 or pcDNA was determined by RT-qPCR. #P<0.05 vs. pcDNA. (F) RT-qPCR was used to detect the expression of miR-150-5p in breast cancer and adjacent tissues. #P<0.05 vs. adjacent tissues. (G) The Kaplan-Meier plotter database was used to analyze the association between miR-150-5p expression and overall survival of patients with breast cancer. Log-rank test was performed to analyze the comparisons between the groups. n=1,262; P=0.013. MAFG-AS1, MAF BZIP transcription factor G antisense RNA 1; miR, microRNA; WT, wild-type; Mut, mutant; RT-qPCR, reverse transcription-quantitative PCR.